Regeneron(US:REGN) Financial Modeling Prep·2026-01-29 12:00Core Viewpoint - Regeneron Pharmaceuticals is a leading biotechnology company focused on developing innovative medicines for serious diseases, competing with major players like Amgen and Biogen [1] Financial Performance - Regeneron is set to release its quarterly earnings on January 30, 2026, with an estimated EPS of $10.56 and revenue of approximately $3.78 billion, while the Zacks Consensus Estimate projects revenues at $3.82 billion [2] - Historically, Regeneron has exceeded earnings estimates in three of the last four quarters, with an average surprise of 21.81% [2] Product Focus - The upcoming earnings report will emphasize profits from the asthma drug Dupixent and sales of Eylea HD, with Eylea's legacy sales declining due to competition, but Eylea HD expected to boost overall franchise revenues [3] - Strong demand for Dupixent across multiple indications is anticipated to drive solid profit growth, offsetting the decline in Eylea sales [3] Stock Performance - Regeneron's stock has increased over 16% since the last analysis, reinforcing a Buy rating, although it is still trading below its all-time high of approximately $1,200 reached in August 2024 [4] - The earnings report could potentially drive the stock price higher if results exceed expectations, while a miss might lead to a decline in stock value [4] Valuation Metrics - Regeneron has a price-to-earnings (P/E) ratio of approximately 17, indicating investors are willing to pay $17 for every $1 of earnings [5] - The company's price-to-sales ratio stands at about 5.44, and the enterprise value to sales ratio is roughly 5.46, indicating consistent valuation metrics [5] - Regeneron demonstrates a solid financial position with a low debt-to-equity ratio of 0.087 and a strong current ratio of 4.06 [5][6]